Aquestive Therapeutics (AQST) Depreciation and Depletion (2018 - 2026)

Aquestive Therapeutics' Depreciation and Depletion history runs 9 years deep, the most recent figure standing at $113000.0 for Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 18.71% year-over-year to $113000.0; the TTM figure through Mar 2026 stood at $522000.0 (down 14.43% YoY), while the FY2025 annual figure was $548000.0, down 14.38% from the prior year.
• Depreciation and Depletion was $113000.0 for Q1 2026 at Aquestive Therapeutics, down from $130000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $714000.0 in Q1 2022 to a low of $113000.0 in Q1 2026.
• Historically, Depreciation and Depletion has averaged $277470.6 across 5 years, with a median of $168000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Depreciation and Depletion advanced 14.24% in 2023, then sank 62.6% in 2024.
• A 5-year view of Depreciation and Depletion shows it stood at $344000.0 in 2022, then climbed by 14.24% to $393000.0 in 2023, then sank by 62.6% to $147000.0 in 2024, then slipped by 11.56% to $130000.0 in 2025, then dropped by 13.08% to $113000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $113000.0 (Q1 2026), $130000.0 (Q4 2025), and $139000.0 (Q3 2025), per Business Quant data.